Complications arise from mesh used in pelvic surgeries

A synthetic mesh commonly used to treat urinary incontinence and weakening of female pelvis walls can lead to complications, new Weill Cornell Medicine research suggests.

Undergrad researchers make pitches at CURBx

At Cornell's version of TEDx Talks – CURBx – seven undergraduate students explained their humanities and STEM research in five-minute presentations Nov. 21 in McGraw Hall.

Barrett, Leibovich and Walsh named AAAS fellows for 2016

Three faculty members - development economist Chris Barrett, mechanical engineer Sidney Leibovich and medical mycologist Dr. Thomas Walsh - have been named fellows of the American Association for the Advancement of Science.

Plant breeders take cues from consumers to improve kale

A Cornell breeding program is targeting the natural biodiversity of kale to further promote its acceptability and popularity as a leafy green vegetable among consumers.

NYC high schoolers discover opportunity at Big Red STEM Day

The first Big Red STEM Day exposed high school students from communities underrepresented in science, technology, engineering and mathematics to educational and career opportunities in those fields.

Cells implicated in dementia related to high blood pressure

High blood pressure transforms cells of the immune system that reside around cerebral blood vessels and normally protect the brain into agents of cognitive decline, according to new research from Weill Cornell Medicine scientists.

Soda prices may only partly bubble up if taxes pass

With soda taxes on the ballot in four cities Nov. 8, and a law on deck in 2017 in another, behavioral economist John Cawley says these taxes have increased soda prices by only half as much as they were intended to.

Public health symposium to take place Nov. 4

The 2016 Cornell University One Health + Public Health + Global Health Symposium will take place Nov. 4, 8 a.m. to 4 p.m., in Biotech G10 and the lobby.

Weill Cornell partners in innovative drug discovery company

Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine announced Oct. 31 that they have established a new drug discovery company called Bridge Medicines.